BridgeBio Pharma, Inc. (BBIO) scores 44 out of 100 on boothcheck's 11-model valuation framework. Verdict: Avoid The estimated fair value is 2.41, representing a 97% premium to fair value. Quantitative score: 41/100. Qualitative score: 80/100.
Analysis includes bear, base, and bull fair value targets using DCF, Graham, regression, and 8 other valuation models.